Anika Therapeutics Toekomstige groei

Future criteriumcontroles 3/6

De omzet van Anika Therapeutics zal naar verwachting dalen met 13.3% per jaar, terwijl de jaarlijkse winst naar verwachting zal groeien met 108.3% per jaar. De winst per aandeel zal naar verwachting groeien met 108.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 4.2% zijn.

Belangrijke informatie

108.3%

Groei van de winst

108.3%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	-13.3%
Toekomstig rendement op eigen vermogen	4.2%
Dekking van analisten	Low
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Recent updates

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Jan 30

Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow

May 28

Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Mar 16

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

Feb 09

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

Jan 13

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Dec 18

Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Winst- en omzetgroeiprognoses

NasdaqGS:ANIK - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	124	5	10	25	2
12/31/2025	115	-3	6	20	2
12/31/2024	150	-39	-2	8	2
9/30/2024	164	-98	-1	7	N/A
6/30/2024	167	-74	1	9	N/A
3/31/2024	169	-77	-4	2	N/A
12/31/2023	167	-83	-7	-2	N/A
9/30/2023	163	-25	-11	-5	N/A
6/30/2023	162	-22	-16	-9	N/A
3/31/2023	157	-22	-5	3	N/A
12/31/2022	156	-15	-3	4	N/A
9/30/2022	152	-16	2	8	N/A
6/30/2022	152	-11	2	8	N/A
3/31/2022	150	-2	3	9	N/A
12/31/2021	148	4	3	8	N/A
9/30/2021	145	-6	2	7	N/A
6/30/2021	137	-13	7	10	N/A
3/31/2021	129	-27	8	10	N/A
12/31/2020	130	-24	11	13	N/A
9/30/2020	128	-4	22	24	N/A
6/30/2020	126	11	26	28	N/A
3/31/2020	125	28	27	30	N/A
12/31/2019	115	27	34	37	N/A
9/30/2019	112	31	31	34	N/A
6/30/2019	109	29	31	35	N/A
3/31/2019	109	30	31	34	N/A
12/31/2018	106	19	30	35	N/A
9/30/2018	108	19	25	32	N/A
6/30/2018	108	18	N/A	33	N/A
3/31/2018	111	20	N/A	35	N/A
12/31/2017	113	32	N/A	41	N/A
9/30/2017	113	32	N/A	40	N/A
6/30/2017	111	34	N/A	39	N/A
3/31/2017	104	31	N/A	32	N/A
12/31/2016	103	33	N/A	24	N/A
9/30/2016	106	36	N/A	34	N/A
6/30/2016	103	35	N/A	31	N/A
3/31/2016	100	34	N/A	43	N/A
12/31/2015	93	31	N/A	40	N/A
9/30/2015	85	28	N/A	39	N/A
6/30/2015	84	25	N/A	37	N/A
3/31/2015	87	27	N/A	30	N/A
12/31/2014	106	38	N/A	40	N/A
9/30/2014	104	37	N/A	33	N/A
6/30/2014	99	36	N/A	33	N/A
3/31/2014	94	33	N/A	33	N/A
12/31/2013	75	21	N/A	25	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat ANIK de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.6% ).

Winst versus markt: Er wordt verwacht dat ANIK de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat ANIK binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van ANIK zal naar verwachting de komende 3 jaar dalen ( -13.3% per jaar).

Hoge groei-inkomsten: De omzet van ANIK zal naar verwachting de komende 3 jaar dalen ( -13.3% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ANIK zal naar verwachting over 3 jaar laag zijn ( 4.2 %).

Anika Therapeutics Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 14% to US$34.50

Anika Therapeutics, Inc. Affirms Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 39%

Recent updates

Anika Therapeutics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Anika Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Price target increased by 14% to US$34.50

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Anika Therapeutics, Inc. Affirms Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Anika Therapeutics, Inc. Announces Full Market Release of the Integrity Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Anika Therapeutics, Inc., Annual General Meeting, Jul 09, 2024

Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares.

Anika Therapeutics, Inc. Announces Board Changes

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Announces CFO Changes

Anika Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

President exercised options and sold US$717k worth of stock

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Anika Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Anika Therapeutics, Inc. Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Anika Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Anika Therapeutics, Inc. announces Completed Enrollment of the Pivotal Phase III Clinical Study for Hyalofast (Hyalofast 15-01) on Its Path to Achieving FDA Approval in the United States

Consensus EPS estimates fall by 39%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

President exercised options and sold US$345k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Anika Therapeutics, Inc.’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

Anika Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Anika Announces First Surgeries Performed Using the X-Twist Fixation System and Commences Limited Market Release

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$40.50

Anika Therapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022

President recently bought US$207k worth of stock

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Anika Therapeutics, Inc. Provides Revenue Guidance for Fiscal 2022

Price target decreased to US$43.75

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider exercised options and sold US$55k worth of stock

Anika Therapeutics, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Third quarter 2021 earnings released: EPS US$0.039 (vs US$0.45 loss in 3Q 2020)

Anika Therapeutics, Inc. Receives an Additional 510(K) Clearance by the Fda for Tactoset® Injectable Bone Substitute

Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.54 loss in 2Q 2020)

Anika Therapeutics, Inc. Revises Earnings Guidance for the Year 2021

Anika Therapeutics, Inc. Announces First Anika Wristmotion Total Wrist Arthroplasty Surgery Performed

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Independent Director Joseph Bower has left the company

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow

Independent Director recently sold US$85k worth of stock

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.41 in 1Q 2020)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Full year 2020 earnings released: US$1.69 loss per share (vs US$1.93 profit in FY 2019)

Earnings beat expectations, revenue disappoints